Cybin Inc. (OTCMKTS:CYBN - Get Free Report)'s share price dropped 0.8% during trading on Monday . The company traded as low as $7.12 and last traded at $7.29. Approximately 292,821 shares were traded during mid-day trading, an increase of 4% from the average daily volume of 280,593 shares. The stock had previously closed at $7.35.
Cybin Stock Performance
The company has a 50 day moving average price of $7.20 and a two-hundred day moving average price of $9.03. The firm has a market capitalization of $151.63 million, a price-to-earnings ratio of -37.16 and a beta of 0.61.
Cybin Company Profile
(
Get Free Report)
Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation.
See Also
Before you consider Cybin, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cybin wasn't on the list.
While Cybin currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Like this article? Share it with a colleague.
Link copied to clipboard.
